Clinical curative effect of flupentixol and melitracen tablets combined with esomeprazole magnesium and mosapride on the treatment of women with chronic gastritis

Objective To discuss the clinical curative effect of flupentixol and melitracen tablets combined with esomeprazole magnesium and mosapride on the treatment of women with chronic gastritis, and to discuss the intervention efficacy on anxious and depressed mood of these patients. Method 118 cases famle patients with chronic gastritis outpatients and inpatients in our hospital were divided randomly into experimental group and control group from January 2011 to October 2014. The patients in experimental group members were given flupentixol and melitracen tablets, esomeprazole and mosapride. The patients in control group were given esomeprazole and mosapride. The treatment lasted for 4 weeks. Pretherapy and post-treatment, patients were given the GSRS-C, HAMA and HAMD evaluation. Result The scores of the two groups were significantly decreased than the beginning and experimental group's scores were significantly lower than control group(P 0.05). Conclusion Flupentixol and melitracen tablets combined with esorneprazole magnesium and mosapride has a more significant clinical curative effect on the treatment of chronic gastritis patients with gastrointestinal symptoms, anxiety and depression can improved significantly, well tolerated.